Showing 2361-2370 of 3329 results for "".
- Merz Aesthetics Marks 15 Years of XEOMIN® With New National Campaignhttps://modernaesthetics.com/news/merz-aesthetics-marks-15-years-of-xeomin-with-new-national-campaign/2485650/Merz Aesthetics is commemorating 15 years since the US Food and Drug Administration (FDA) approved XEOMIN® (incobotulinumtoxinA) for aesthetic use, marking a milestone for the company’s flagship neurotoxin in the competitive US injectable market. Approved f
- A Whole-Face, Whole-Patient Framework Review for Aesthetic Consultationhttps://modernaesthetics.com/news/a-whole-face-whole-patient-framework-review-for-aesthetic-consultation/2485626/Aesthetic facial rejuvenation is increasingly defined by comprehensive, patient-centered assessment rather than isolated correction of individual features, according to a multidisciplinary review published in Dermatologic Surgery. Drawing on insights from dermatology, plastic surgery, an
- Prolactin Receptor Blockade May Promote Hair Growth via Follicular Stem Cell Activationhttps://modernaesthetics.com/news/prolactin-receptor-blockade-may-promote-hair-growth-via-follicular-stem-cell-activation/2485612/Blocking prolactin receptor (PRLR) signaling with the investigational antibody ABS-201 promoted hair follicle growth and stem cell activation in human male scalp skin models, according to preclinical data from Jérémy Chéret, PhD, MSc, at the South Beach Symposium
- Micro-Autologous Fat Transplantation Shows Durable Correction for Gummy Smile in Long-Term Studyhttps://modernaesthetics.com/news/micro-autologous-fat-transplantation-shows-durable-correction-for-gummy-smile-in-long-term-study/2485602/Micro-autologous fat transplantation (MAFT) may offer a durable, minimally invasive option for correcting gummy smile, according to a long-term retrospective study published online ahead of print in Plastic and Reconstructive Surgery. Investigators analyzed outcomes in 52 patients
- Octane Aesthetics Tech Forum: Panelists Discuss Innovation in Hair Loss Delivery, Regulationhttps://modernaesthetics.com/news/octane-aesthetics-tech-forum-panelists-discuss-innovation-in-hair-loss-delivery-regulation/2485561/The future of hair restoration may be rooted in regenerative science, but panelists at the Octane Aesthetics Tech Forum agree: the real-world success of these advances hinges on how treatments are delivered and how they’re regulated. Speaking during the “Hiding in the Shadows of H
- Octane Aesthetics Tech Forum: GLP-1 Receptor Agonists Are Reshaping Consumer Behavior and Aesthetic Business Modelshttps://modernaesthetics.com/news/octane-aesthetics-tech-forum-glp-1-receptor-agonists-are-reshaping-consumer-behavior-and-aesthetic-business-models/2485431/The rise of GLP-1 receptor agonist (GLP-1RA) medications is doing more than transforming bodies; it is reshaping the very business of aesthetics. At the 2026 Octane Aesthetics Tech Forum, panelists described how GLP-1RAs are influencing patient behavior, redefining value propositions, and catalyz
- skinbetter science® Marks 10 Years of AlphaRet® Technology in Retinoid-AHA Skincarehttps://modernaesthetics.com/news/skinbetter-science-marks-10-years-of-alpharet-technology-in-retinoid-aha-skincare/2485358/skinbetter science® is marking the 10-year anniversary of its proprietary AlphaRet® technology, introduced in 2016 as one of the first topical skincare formulas to combine a retinoid with an alpha hydroxy acid (AHA). The combination, used in the flagship AlphaRet Overnight Cream, was designed to
- FDA Approves RHA® Dynamic Volume for Midface Augmentationhttps://modernaesthetics.com/news/fda-approves-rha-dynamic-volume-for-midface-augmentation/2485309/The US Food and Drug Administration (FDA) has approved RHA® Dynamic Volume from the Teoxane RHA® Collection for cheek augmentation and correction of age-related midface contour deficiencies in adults 22 and older, Revance and Teoxane announced.
- FDA Approves Once-Daily Oral Semaglutidehttps://modernaesthetics.com/news/fda-approves-once-daily-oral-semaglutide/2485258/The US Food and Drug Administration (FDA) has approved Novo Nordisk’s once-daily oral formulation of semaglutide, marketed as Wegovy® pill, marking the first oral GLP-1 receptor agonist approved for chronic weight management in the United States. The approval includes indications for adults with
- FDA: Most PFAS in Cosmetics Lack Adequate Safety Datahttps://modernaesthetics.com/news/fda-most-pfas-in-cosmetics-lack-adequate-safety-data/2485144/The U.S. Food and Drug Administration (FDA) announced that it has released its first congressionally mandated report under the Modernization of Cosmetics Regulation Act of 2022 (MoCRA), assessing the use and safety of perfluoroalkyl and polyfluoroalkyl substances (PF